Yaz ad gets FDA-OK make-over
Bayer is airing a corrective television ad campaign for its oral contraceptive Yaz (drospirenone/ethinyl estradiol), in response to an agency warning letter it received last fall (1"The Pink Sheet," Oct. 13, 2008, p. 21). The campaign will more clearly say Yaz is indicated to treat symptoms for premenstrual dysphoric disorder, not premenstrual syndrome, and moderate, not mild, acne. The ad is markedly different from the 2008 campaign and features one woman talking about the product and indications (with no balloons), Bayer said. It will run through August
You may also be interested in...
FDA's Division of Drug Marketing, Advertising and Communications has sent half of this year's citations for misleading advertising in the past month
It’s the third high-risk class I action in recent weeks related to the company’s HeartWare Ventricular Assist Device (HVAD) System. It’s also Medtronic’s sixth overall class I since the beginning of March.
Eye disease drugs have struggled to grow during the pandemic but Bayer's Regeneron-partnered blockbuster is going from strength to strength, helped by growth in Japan.